| Next 10 |
Ad
SOLTF News and Press Nxera Pharma Co Ltd Ord
home / stock / soltf / soltf news
News | Nxera Pharma Co Ltd Ord (OTCMKTS:SOLTF)
-
Phase 2 trial initiation in patients with sleep /wake disorders results in milestone payment of US$3.5 million to Nxera Tokyo, Japan and Cambridge, UK, 13 November 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – form...
-
Tokyo, Japan and London and Cardiff, UK, 5 November 2024 – Nxera Pharma (“Nxera”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – and Antiverse, a techbio company designing antibodies for challenging targets, have today announced a multi-target p...
-
Tokyo, Japan and Cambridge, UK, 1 November 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – provides an update on operational activities and reports its consolidated re...
-
Tokyo, Japan and Cambridge, UK, 23 October 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – is pleased to announce that it has won Biotech Company of the Year and Finan...
-
Nxera Pharma Co., Ltd. will hold an R&D Day on 6 November 2024 at 16:30 JST. The meeting will be held virtually via Zoom webinar. Please click here to pre-register for the event. Date : Wednesday, 6 November 2024 Time : 16:30 – 18:00 JST (7:30 – 9:00 GMT) ...
-
Dr. Sugita – formerly Vice President, Head of R&D for Bristol Myers Squibb in Japan – brings nearly 20 years’ experience in R&D and commercial roles working within the Japanese businesses of global pharmaceutical companies Tokyo, Japan and Cambridge, UK, ...
-
QUVIVIQ™ is a potential best-in-class treatment in the high-growth, dual orexin antagonist class of medicines treating sleep disorders, such as insomnia Tokyo, Japan and Cambridge, UK, 1 October 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Co...
-
The approval of QUVIVIQ™, a novel dual orexin receptor antagonist, is based on robust clinical efficacy and safety data, including from a Phase 3 trial in Japan that met all primary and secondary endpoints Plans to make QUVIVIQ available as soon as possible to insomnia patients in Japa...
-
HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist with the potential to treat a wide range of cancers in combination with other immunotherapies Cancer Research UK’s Centre for Drug Development is sponsoring and managing the ongoing Phase 1/2a clinical tr...
-
ORX750 showed clinically meaningful and statistically significant improvements in mean sleep latency and had a favorable safety and tolerability profile with no observations of frequently reported adverse events Centessa plans to rapidly advance ORX750 into Phase 2 studies beginning in the fo...
Stock Information
Get SOLTF Alerts
News, Short Squeeze, Breakout and More Instantly...
Nxera Pharma Co Ltd Ord Company Name:
SOLTF Stock Symbol:
OTCMKTS Market:
Ad
-
Phase 2 trial initiation in patients with sleep /wake disorders results in milestone payment of US$3.5 million to Nxera Tokyo, Japan and Cambridge, UK, 13 November 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – form...
-
Tokyo, Japan and London and Cardiff, UK, 5 November 2024 – Nxera Pharma (“Nxera”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – and Antiverse, a techbio company designing antibodies for challenging targets, have today announced a multi-target p...
-
Tokyo, Japan and Cambridge, UK, 1 November 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – provides an update on operational activities and reports its consolidated re...